

Supplemental table 4  
Cox regression in subgroups  
discovery cohort

Characteristic	PFS				OS			
	N	HR <sup>1</sup>	95% CI <sup>1</sup>	p-value	N	HR <sup>1</sup>	95% CI <sup>1</sup>	p-value
<b>concurrent chemotherapy</b>								
<b>ICB monotherapy</b>	47				47			
Non-Responder		—	—			—	—	
Responder		0.22	0.10, 0.48	<b>&lt;0.001</b>		0.24	0.11, 0.52	<b>&lt;0.001</b>
Flare-Responder		0.26	0.09, 0.74	<b>0.011</b>		0.28	0.10, 0.76	<b>0.013</b>
<b>concurrent chemotherapy</b>	55				55			
Non-Responder		—	—			—	—	
Responder		0.70	0.26, 1.90	0.5		0.52	0.22, 1.25	0.14
Flare-Responder		0.95	0.35, 2.57	>0.9		0.73	0.31, 1.73	0.5
<b>line of therapy</b>								
<b>first line</b>	70				69			
Non-Responder		—	—			—	—	
Responder		0.44	0.20, 0.97	<b>0.041</b>		0.50	0.24, 1.00	0.052
Flare-Responder		0.38	0.15, 0.96	<b>0.040</b>		0.42	0.18, 0.98	<b>0.045</b>
<b>higher lines</b>	34				33			
Non-Responder		—	—			—	—	
Responder		0.11	0.03, 0.43	<b>0.002</b>		0.17	0.05, 0.63	<b>0.008</b>
Flare-Responder		0.40	0.15, 1.12	0.080		0.58	0.23, 1.45	0.2
<b>concurrent steroid medication</b>								
<b>no concurrent steroid medication</b>	76				76			
Non-Responder		—	—			—	—	
Responder		0.28	0.14, 0.55	<b>&lt;0.001</b>		0.32	0.17, 0.61	<b>&lt;0.001</b>
Flare-Responder		0.26	0.12, 0.60	<b>0.001</b>		0.31	0.14, 0.66	<b>0.002</b>
<b>concurrent steroid medication</b>	26				26			
Non-Responder		—	—			—	—	
Responder		0.49	0.12, 1.95	0.3		0.36	0.10, 1.39	0.14
Flare-Responder		2.12	0.66, 6.81	0.2		1.36	0.48, 3.85	0.6

<sup>1</sup> HR = Hazard Ratio, CI = Confidence Interval